AU752701B2 - Tumour suppressor gene DBCCR1 at 9q32-33 - Google Patents

Tumour suppressor gene DBCCR1 at 9q32-33 Download PDF

Info

Publication number
AU752701B2
AU752701B2 AU75425/98A AU7542598A AU752701B2 AU 752701 B2 AU752701 B2 AU 752701B2 AU 75425/98 A AU75425/98 A AU 75425/98A AU 7542598 A AU7542598 A AU 7542598A AU 752701 B2 AU752701 B2 AU 752701B2
Authority
AU
Australia
Prior art keywords
nucleic acid
polypeptide
dbccr1
cancer
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU75425/98A
Other languages
English (en)
Other versions
AU7542598A (en
Inventor
Tomonori Habuchi
Margaret Knowles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Horizons Ltd
Original Assignee
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Cancer Research Technology Ltd filed Critical Imperial Cancer Research Technology Ltd
Publication of AU7542598A publication Critical patent/AU7542598A/en
Application granted granted Critical
Publication of AU752701B2 publication Critical patent/AU752701B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU75425/98A 1997-05-28 1998-05-26 Tumour suppressor gene DBCCR1 at 9q32-33 Ceased AU752701B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9710995.3A GB9710995D0 (en) 1997-05-28 1997-05-28 Tumour suppressor locus and gene at 9q32-33
GB9710995 1997-05-28
PCT/GB1998/001515 WO1998054318A1 (en) 1997-05-28 1998-05-26 TUMOUR SUPPRESSOR GENE DBCCR1 AT 9q32-33

Publications (2)

Publication Number Publication Date
AU7542598A AU7542598A (en) 1998-12-30
AU752701B2 true AU752701B2 (en) 2002-09-26

Family

ID=10813172

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75425/98A Ceased AU752701B2 (en) 1997-05-28 1998-05-26 Tumour suppressor gene DBCCR1 at 9q32-33

Country Status (6)

Country Link
EP (1) EP0983355A1 (ja)
JP (1) JP2002511749A (ja)
AU (1) AU752701B2 (ja)
CA (1) CA2288235A1 (ja)
GB (1) GB9710995D0 (ja)
WO (1) WO1998054318A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743909B2 (en) * 2002-06-17 2004-06-01 Isis Pharmaceuticals, Inc. Antisense modulation of PTPN12 expression
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
WO2000001816A1 (en) * 1998-07-02 2000-01-13 Imperial Cancer Research Technology Limited TUMOUR SUPPRESSOR GENE DBCCR1 AT 9q32-33
US6994991B1 (en) 1998-11-18 2006-02-07 North Shore - Long Island Jewish Research Institute Identification of differentially methylated multiple drug resistance loci
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
JP2008029293A (ja) * 2006-07-31 2008-02-14 Hisamitsu Pharmaceut Co Inc 癌の治療薬のスクリーニング方法及び癌の治療薬
EP2198042B1 (en) 2007-09-17 2016-11-02 MDxHealth SA Novel markers for bladder cancer detection
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
EP2392679B1 (en) * 2007-11-30 2013-09-11 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9797017B2 (en) 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
WO2018050844A1 (en) 2016-09-16 2018-03-22 Qiagen Gmbh Method for determining nucleic acid degradation in a sample in which at least two overlapping amplicons are produced and two probes are used in the method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENBANK ACCESSION NO.S AA326334, AA319716, AA011152 *

Also Published As

Publication number Publication date
EP0983355A1 (en) 2000-03-08
WO1998054318A1 (en) 1998-12-03
JP2002511749A (ja) 2002-04-16
GB9710995D0 (en) 1997-07-23
AU7542598A (en) 1998-12-30
CA2288235A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
Habuchi et al. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32–q33
US7368255B2 (en) RUNX3 gene showing anti-tumor activity and use thereof
Nakamura et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t (7; 11)(p15; p15) in human myeloid leukaemia
Carroll et al. p53 oncogene mutations in three human prostate cancer cell lines
AU752701B2 (en) Tumour suppressor gene DBCCR1 at 9q32-33
EP0821733B1 (en) Genetic markers for breast and ovarian cancer
EP1762619B1 (en) Multiple-tumor aberrant growth genes
US20060024780A1 (en) Wwox: a tumor suppressor gene mutated in multiple cancers
WO1996013514A1 (en) Tcl-1 gene and protein and related methods and compositions
EP0837935B1 (en) 3' utr of the human prohibitin gene
WO1996002641A2 (en) Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma
WO1993022435A1 (en) Fanconi anemia gene for complementation group c
Grötzinger et al. A highly amplified mouse gene is homologous to the human interferon-responsive Sp100 gene encoding an autoantigen associated with nuclear dots
WO2000001816A1 (en) TUMOUR SUPPRESSOR GENE DBCCR1 AT 9q32-33
EP0825198A1 (en) Plag gene family and tumorigenesis
EP0727486A2 (en) Tumour suppressor gene
US6551781B1 (en) Methods of screening for compounds that regulate the level of Nramp
US5556945A (en) Tumor suppressor gene
EP0809698A1 (en) NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF TUMOR GENE Int6
US6350867B1 (en) Compositions and methods for enhancing osseous growth, repair and regeneration
WO2001018037A2 (en) A p53-induced protein with a death domain that can promote apoptosis
JP2000512133A (ja) 多発性骨髄腫で変化した遺伝子の同定
JPH11508767A (ja) マウス腫瘍拒絶抗原前駆体ｓｍａｇｅ−３をコードする単離核酸分子
WO1999043812A2 (en) Dlc-1 gene, a putative tumors suppressor gene
Carroll et al. p53 zyxwvutsrqponmlkjihgfe

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired